Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 200Neoplasms 116Breast Neoplasms 112Colorectal Neoplasms 97Ovarian Neoplasms 78Prostatic Neoplasms 75Neoplasm Metastasis 74Lung Neoplasms 66Multiple Myeloma 64Squamous Cell Carcinoma of Head and Neck 49Pancreatic Neoplasms 48Endometrial Neoplasms 48Recurrence 46Stomach Neoplasms 39Carcinoma, Renal Cell 39Small Cell Lung Carcinoma 38Melanoma 38Leukemia, Lymphocytic, Chronic, B-Cell 38Leukemia, Myeloid, Acute 34Lymphoma, Non-Hodgkin 30Urinary Bladder Neoplasms 29Parkinson Disease 4, Autosomal Dominant Lewy Body 29Triple Negative Breast Neoplasms 28Head and Neck Neoplasms 26Carcinoma, Hepatocellular 26Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 25Esophageal Neoplasms 24Advanced Solid Tumors 24Lymphoma 23

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Immune System Diseases × 30 days × Clear all
NCT05826535 2026-05-28

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma, Inc.

Phase 1/2 Recruiting
270 enrolled
Lymphoid

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡